Fingerprint
Dive into the research topics of 'Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
R. A. Mesa
Research output: Contribution to journal › Review article › peer-review
88
Scopus
citations